Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17126942 | TEMPERATURE-SENSITIVE CELL CULTURE COMPOSITION, METHOD FOR USING THE SAME, METHOD FOR FORMING THE SAME, AND USE THEREOF | December 2020 | October 2024 | Allow | 46 | 2 | 1 | No | No |
| 17118814 | ENZYME-POROUS CARBON COMPOSITE | December 2020 | October 2021 | Allow | 10 | 2 | 0 | Yes | No |
| 16973625 | COMPOSITION FOR CELL TRANSPLANT, AND METHOD FOR CELL TRANSPLANT | December 2020 | March 2023 | Allow | 27 | 1 | 0 | No | No |
| 17112020 | Drug Carrier, Brain-targeting Nanodrug Based on CRISPR Gene Editing Technology and Preparation Method and Use thereof | December 2020 | August 2024 | Allow | 45 | 2 | 1 | No | No |
| 17107468 | SYSTEM AND METHOD FOR MICRONEEDLE DELIVERY OF MICROENCAPSULATED VACCINE AND BIOACTIVE PROTEINS | November 2020 | February 2023 | Allow | 27 | 1 | 0 | No | No |
| 17091075 | METHODS AND PRODUCTS FOR IN VIVO ENZYME PROFILING | November 2020 | January 2023 | Allow | 26 | 1 | 0 | No | No |
| 17087294 | GASTROINTESTINAL TRACT THERAPEUTIC AGENTS | November 2020 | September 2024 | Abandon | 46 | 3 | 0 | No | No |
| 17078319 | De Novo Designed Non-Local Beta Sheet Proteins | October 2020 | June 2023 | Allow | 32 | 1 | 1 | No | No |
| 17073439 | SYNTHESIS OF GLUCAN COMPRISING ALPHA-1,3 GLYCOSIDIC LINKAGES WITH PHOSPHORYLASE ENZYMES | October 2020 | June 2022 | Allow | 20 | 0 | 0 | No | No |
| 17071341 | PLANT-DERIVED ELASTIN BINDING PROTEIN LIGANDS AND METHODS OF USING THE SAME | October 2020 | December 2022 | Abandon | 26 | 0 | 1 | No | No |
| 17034858 | ORAL DISSOLVING FILMS CONTAINING MICROENCAPSULATED VACCINES AND METHODS OF MAKING SAME | September 2020 | September 2022 | Allow | 24 | 1 | 0 | Yes | No |
| 17042682 | PEPTIDES AND CONJUGATES | September 2020 | September 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 17041363 | BETA BARREL POLYPEPTIDES AND METHODS FOR THEIR USE | September 2020 | May 2024 | Allow | 43 | 1 | 1 | No | No |
| 17021130 | METHOD OF DECELLULARIZATION OF KIDNEY TISSUES, DECELLULARIZED MATERIAL BY THE METHOD AND BIOINK COMPRISING THE DECELLULARIZED MATERIAL | September 2020 | May 2023 | Allow | 32 | 1 | 1 | No | No |
| 16980027 | METHOD FOR DETERMINING THE ANTIOXIDANT CAPACITY OF A BIOLOGICAL SAMPLE AND RELATED KIT | September 2020 | June 2025 | Abandon | 57 | 2 | 1 | No | No |
| 16980178 | MICROPEPTIDES AND USES THEREOF | September 2020 | September 2023 | Allow | 36 | 2 | 1 | Yes | No |
| 17011981 | ENGINEERED YEAST AS A METHOD FOR BIOREMEDIATION | September 2020 | August 2023 | Allow | 35 | 2 | 1 | Yes | Yes |
| 15733545 | VIRAL TREATMENT | August 2020 | May 2023 | Allow | 32 | 2 | 1 | Yes | No |
| 16998349 | LACTOFERRIN COMPOSITIONS AND METHODS FOR MODULATION OF T CELL SUBTYPES AND TREATMENT OF AUTOIMMUNE DISEASES | August 2020 | December 2022 | Abandon | 28 | 1 | 1 | No | No |
| 16994330 | THROMBOSOMES AS AN ANTICOAGULANT REVERSAL AGENT | August 2020 | March 2025 | Abandon | 56 | 4 | 0 | Yes | No |
| 16985302 | POLYPEPTIDE VARIANTS | August 2020 | April 2022 | Allow | 21 | 1 | 0 | No | No |
| 16942666 | MULTIPLE RAPID DETECTION KITS AND METHODS FOR VARIOUS VIRUSES | July 2020 | August 2022 | Allow | 25 | 3 | 1 | Yes | No |
| 16926205 | RNA-TARGETING KNOCKDOWN AND REPLACEMENT COMPOSITIONS AND METHODS FOR USE | July 2020 | July 2024 | Abandon | 48 | 2 | 1 | No | No |
| 16922377 | METHOD OF PREPARING CORN GLYCOPEPTIDES, AND PRODUCT AND USE THEREOF | July 2020 | July 2023 | Abandon | 36 | 1 | 1 | No | No |
| 16946333 | TREATMENT OF ISCHEMIA | June 2020 | December 2021 | Allow | 18 | 1 | 0 | No | No |
| 16954567 | LAS-CONTAINING CLEANING AGENTS WITH SYNERGISTICALLY ACTING PROTEASES AND AMYLASES | June 2020 | August 2022 | Allow | 26 | 1 | 1 | No | No |
| 16903258 | IN VIVO ENGINEERED CEREBLON PROTEIN | June 2020 | July 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16902001 | PENICILLIN-G ACYLASES | June 2020 | August 2021 | Allow | 14 | 1 | 0 | No | No |
| 16898966 | METHODS OF SHIFTING AN ISOELECTRIC PROFILE OF A PROTEIN PRODUCT AND USES THEREOF | June 2020 | February 2024 | Allow | 44 | 2 | 1 | No | No |
| 16894600 | MICROORGANISMS FOR PRODUCING 1,3-BUTANEDIOL AND METHODS RELATED THERETO | June 2020 | March 2023 | Allow | 33 | 2 | 0 | No | No |
| 16891449 | MODIFIED TEMPLATE-INDEPENDENT ENZYMES FOR POLYDEOXYNUCLEOTIDE SYNTHESIS | June 2020 | March 2022 | Allow | 21 | 1 | 0 | No | No |
| 16891835 | COMPOSITIONS COMPRISING DIGESTIVE ENZYMES | June 2020 | December 2020 | Allow | 7 | 1 | 0 | Yes | No |
| 16766651 | NOVEL PEPTIDE FOR ENHANCING EXPRESSION EFFICIENCY OF TARGET PROTEIN, AND FUSION PROTEIN COMPRISING SAME | May 2020 | November 2022 | Allow | 30 | 1 | 1 | No | No |
| 16765649 | PRODUCTION OF GUAIENE AND ROTUNDONE | May 2020 | July 2022 | Allow | 26 | 2 | 1 | Yes | No |
| 16765553 | COMPOSITION FOR GENOME EDITING USING CRISPR/CPF1 SYSTEM AND USE THEREOF | May 2020 | April 2023 | Allow | 35 | 1 | 1 | No | No |
| 16762547 | SILK-BASED PRODUCTS AND METHODS OF USE | May 2020 | December 2022 | Abandon | 31 | 0 | 1 | No | No |
| 16761677 | FUSION PROTEINS WITH SPECIFICITY FOR ED-B AND LONG SERUM HALF-LIFE FOR DIAGNOSIS OR TREATMENT OF CANCER | May 2020 | April 2022 | Allow | 23 | 0 | 1 | No | No |
| 16866361 | C-PEPTIDES AND PROINSULIN POLYPEPTIDES COMPRISING THE SAME | May 2020 | December 2021 | Allow | 19 | 0 | 0 | No | No |
| 16759975 | CALCIUM-CHELATING PEPTIDES DERIVED FROM EF-HAND CALCIUM-BINDING MOTIF | April 2020 | February 2023 | Allow | 34 | 1 | 1 | No | No |
| 16759703 | Cyclic GMP-Chelating Peptides for Subcellular Targetting | April 2020 | August 2022 | Allow | 27 | 1 | 1 | No | No |
| 16758653 | IMPROVED METHOD FOR PURIFICATION OF IMMUNOGLOBULIN | April 2020 | November 2022 | Allow | 30 | 1 | 0 | No | No |
| 16857089 | A PAIR OF AMINO ACID SEQUENCES FOR MONITORING FORMATION OF TDP-43 OLIGOMER IN LIVING CELLS VIA BIMOLECULAR FLUORESCENCE COMPLEMENTATION | April 2020 | June 2022 | Allow | 25 | 1 | 1 | No | No |
| 16757993 | BETA-AMYLASE ENZYMES | April 2020 | August 2022 | Allow | 28 | 1 | 1 | No | No |
| 16853444 | Virus filtration of liquid factor VII compositions | April 2020 | December 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16756887 | MODULATED CAS-INHIBITORS | April 2020 | June 2024 | Allow | 50 | 4 | 1 | Yes | No |
| 16847206 | SYSTEMS, METHODS, AND COMPOSITIONS TO IDENTIFY NEW PROTEIN TARGETS OF A CHEMICAL COMPOUND OR ITS DERIVATIVES | April 2020 | March 2023 | Abandon | 35 | 2 | 1 | No | No |
| 16648919 | ENGINEERED DECARBOXYLASE POLYPEPTIDES AND THEIR APPLICATION IN PREPARING BETA-ALANINE | March 2020 | March 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16820421 | ALBUMIN VARIANTS AND CONJUGATES | March 2020 | June 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16818827 | GLYCAN-BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS | March 2020 | October 2022 | Allow | 31 | 2 | 1 | Yes | No |
| 16816486 | CHARGE-REVERSED N-TERMINAL SPIDER SILK PROTEIN DOMAIN AND USES THEREOF | March 2020 | August 2021 | Allow | 18 | 1 | 0 | No | No |
| 16643355 | METHOD FOR PURIFYING A SULFATASE PROTEIN | February 2020 | November 2022 | Allow | 33 | 1 | 0 | No | No |
| 16791055 | COMPOSITION AND METHODS FOR PREVENTING OR REDUCING THE INCIDENCE OF TRANSIENT ISCHEMIC ATTACKS | February 2020 | July 2021 | Allow | 17 | 1 | 0 | No | No |
| 16633589 | Modified Fibroin | January 2020 | February 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16749584 | POLYMER-BASED SUSTAINED RELEASE DEVICE | January 2020 | July 2024 | Abandon | 54 | 1 | 0 | No | No |
| 16632155 | NOVEL MUTATED PTE ENZYMES | January 2020 | May 2022 | Allow | 28 | 2 | 0 | No | No |
| 16632090 | BLOOD SUBSTITUTES COMPRISING HEMOGLOBIN AND METHODS OF MAKING | January 2020 | May 2022 | Allow | 28 | 1 | 1 | Yes | No |
| 16739407 | SYNTHETIC ONCOLYTIC LNP-REPLICON RNA AND USES FOR CANCER IMMUNOTHERAPY | January 2020 | March 2023 | Allow | 38 | 1 | 1 | No | No |
| 16630396 | METAL NANOCLUSTER SCAFFOLDS | January 2020 | March 2022 | Allow | 26 | 1 | 1 | No | No |
| 16629255 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | January 2020 | May 2021 | Abandon | 16 | 0 | 0 | No | No |
| 16734256 | MODIFIED UROKINASE-TYPE PLASMINOGEN ACTIVATOR POLYPEPTIDES AND METHODS OF USE | January 2020 | November 2022 | Allow | 34 | 1 | 1 | No | No |
| 16628258 | NOVEL HYALURONIDASE VARIANTS AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | January 2020 | July 2024 | Allow | 60 | 2 | 1 | Yes | No |
| 16719097 | Proteinases with Improved Properties | December 2019 | March 2020 | Allow | 2 | 0 | 0 | No | No |
| 16719833 | CO-PRODUCTION PATHWAY FOR 3-HPA AND ACETYL-COA DERIVATIVES FROM MALONATE SEMIALDEHYDE | December 2019 | February 2022 | Allow | 26 | 1 | 1 | No | No |
| 16621493 | Xylanase Variants and Polynucleotides Encoding Same | December 2019 | July 2022 | Allow | 31 | 1 | 1 | No | No |
| 16619119 | Method for detecting food spoilage microbes | December 2019 | November 2021 | Allow | 23 | 1 | 0 | No | No |
| 16618787 | METHOD FOR EXTRACTING TARGET PROTEIN FROM BIOLOGICAL SAMPLE AND METHOD FOR ANALYZING TARGET PROTEIN | December 2019 | January 2025 | Allow | 60 | 4 | 1 | No | No |
| 16617635 | Protein Molded Article And Method For Producing Same, Protein Solution, And Protein Molded Article Plasticizer | November 2019 | February 2024 | Abandon | 50 | 2 | 1 | Yes | No |
| 16616827 | Protease and Binding Polypeptide for O-Glycoproteins | November 2019 | September 2022 | Allow | 34 | 2 | 1 | Yes | No |
| 16494796 | RNA-BINDING PROTEIN | November 2019 | February 2022 | Allow | 29 | 1 | 1 | No | No |
| 16616041 | PENICILLIN-G ACYLASES | November 2019 | December 2022 | Allow | 37 | 4 | 0 | No | No |
| 16616059 | METHODS FOR THAXTOMIN PRODUCTION AND ENGINEERED NON-NATIVE STREPTOMYCES WITH INCREASED THAXTOMIN PRODUCTION | November 2019 | February 2022 | Allow | 26 | 3 | 1 | Yes | No |
| 16611688 | HUMAN PORPHOBILINOGEN DEAMINASE DERIVED PROTEINS AND POLYNUCLEOTIDES AND USES THEREOF | November 2019 | March 2022 | Allow | 29 | 2 | 0 | No | No |
| 16611053 | RECOMBINANT MICROORGANISM, METHOD OF PRODUCING PYRIDOXAMINE OR SALT THEREOF USING RECOMBINANT MICROORGANISM, AND METHOD OF PRODUCING PYRIDOXAL OR SALT THEREOF USING RECOMBINANT MICROORGANISM | November 2019 | September 2021 | Abandon | 22 | 0 | 1 | No | No |
| 16669051 | METHODS FOR PRODUCTION OF OXYGENATED TERPENES | October 2019 | June 2021 | Allow | 20 | 1 | 0 | No | No |
| 16607508 | SIALIC ACID BINDING POLYPEPTIDE | October 2019 | April 2022 | Allow | 30 | 2 | 1 | No | No |
| 16605591 | METHODS OF PURIFICATION OF ALBUMIN FUSION PROTEINS | October 2019 | December 2021 | Abandon | 26 | 2 | 0 | No | No |
| 16603639 | GLUCOAMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME | October 2019 | November 2021 | Allow | 25 | 1 | 1 | No | No |
| 16500465 | CLEANING COMPOSITIONS AND USES THEREOF | October 2019 | March 2022 | Allow | 30 | 2 | 1 | No | No |
| 16500475 | CLEANING COMPOSITIONS AND USES THEREOF | October 2019 | September 2021 | Abandon | 23 | 0 | 1 | No | No |
| 16588517 | NOVEL AGENTS AND METHODS FOR DIAGNOSING FISH ALLERGY | September 2019 | January 2023 | Allow | 39 | 1 | 1 | No | No |
| 16497825 | APPLICATION OF GENETICALLY ENGINEERED BACTERIA VNP20009-M IN PREPARING DRUG FOR TREATING MALIGNANT SARCOMA | September 2019 | March 2022 | Allow | 29 | 1 | 0 | No | No |
| 16582959 | COMPOSITIONS AND METHODS FOR TREATING CONTAMINATED WATER | September 2019 | November 2021 | Allow | 25 | 1 | 1 | No | No |
| 16579445 | METHODS AND COMPOSITIONS FOR RAPIDLY REPLACING CARDIAC MYOSIN BINDING PROTEIN-C IN SARCOMERES | September 2019 | September 2021 | Allow | 24 | 2 | 1 | Yes | No |
| 16577093 | COMPOSITIONS AND METHODS FOR IMPROVED ENCAPSULATION OF FUNCTIONAL PROTEINS IN POLYMERIC VESICLES | September 2019 | March 2021 | Allow | 18 | 1 | 0 | No | No |
| 16495161 | POLYPEPTIDES HAVING RNASE ACTIVITY | September 2019 | July 2021 | Allow | 22 | 1 | 1 | No | No |
| 16495147 | POLYPEPTIDES HAVING DNASE ACTIVITY | September 2019 | July 2021 | Allow | 22 | 2 | 0 | Yes | No |
| 16570881 | METHODS FOR REGULATING NITROGEN METABOLISM DURING THE PRODUCTION OF ETHANOL FROM CORN BY METABOLICALLY ENGINEERED YEAST STRAINS | September 2019 | November 2021 | Allow | 26 | 1 | 1 | Yes | No |
| 16492553 | CYTOSINE TO GUANINE BASE EDITOR | September 2019 | August 2022 | Allow | 35 | 2 | 1 | Yes | No |
| 16491640 | Highly Contracted Synthetic Fibroin Fiber, Production Method Therefor, and Method for Contracting Synthetic Fibroin Fiber | September 2019 | February 2024 | Allow | 53 | 3 | 0 | Yes | No |
| 16563508 | PROCESS FOR BIO-SLUDGE REDUCTION IN HYDROCARBON REFINERY EFFLUENT TREATMENT PLANT THROUGH MICROBIAL INTERVENTIONS | September 2019 | February 2021 | Allow | 17 | 1 | 0 | No | No |
| 16491093 | Method for Degumming and Refining of Vegetable Oil | September 2019 | December 2022 | Abandon | 39 | 2 | 1 | No | Yes |
| 16557755 | Methods and Compositions for Synthesizing Improved Silk Fibers | August 2019 | April 2021 | Allow | 19 | 0 | 0 | No | No |
| 16552304 | PROCESS FOR ENZYMATIC HYDROLYSIS OF LIGNOCELLULOSIC MATERIAL AND FERMENTATION OF SUGARS | August 2019 | March 2021 | Allow | 18 | 2 | 0 | Yes | No |
| 16541158 | METHOD FOR THE PREPARATION OF LOW MOLECULAR WEIGHT PORCINE LYMPHO-RETICULAR POLYPEPTIDES | August 2019 | November 2020 | Allow | 15 | 0 | 0 | No | No |
| 16536227 | IN VIVO ENGINEERED CEREBLON PROTEIN | August 2019 | March 2020 | Allow | 7 | 1 | 0 | Yes | No |
| 16519951 | COMPOSITION FOR REDUCING NERVOUS SYSTEM INJURY AND METHOD OF MAKING AND USE THEREOF | July 2019 | December 2020 | Allow | 17 | 1 | 0 | No | No |
| 16519690 | PROTEIN-POLYMER HYBRID BIOMATERIALS | July 2019 | September 2022 | Allow | 38 | 2 | 1 | No | No |
| 16478777 | MICROBIAL CONSORTIUM FOR 1,3-PROPANEDIOL PRODUCTION USING HIGH GLYCEROL CONCENTRATION | July 2019 | January 2021 | Allow | 18 | 1 | 0 | No | No |
| 16477907 | PHYTASE VARIANTS YKAPPA HAVING IMPROED PEPSIN RESISTANCE AND INCREASED CATALYTIC EFFICIENCY | July 2019 | February 2021 | Allow | 19 | 0 | 1 | No | No |
| 16512072 | Terpene Synthases for Biofuel Production and Methods Thereof | July 2019 | December 2020 | Allow | 17 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DESAI, ANAND U.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DESAI, ANAND U works in Art Unit 1656 and has examined 959 patent applications in our dataset. With an allowance rate of 74.3%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 34 months.
Examiner DESAI, ANAND U's allowance rate of 74.3% places them in the 41% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by DESAI, ANAND U receive 1.71 office actions before reaching final disposition. This places the examiner in the 33% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by DESAI, ANAND U is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +22.2% benefit to allowance rate for applications examined by DESAI, ANAND U. This interview benefit is in the 66% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 30.7% of applications are subsequently allowed. This success rate is in the 64% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 58.9% of cases where such amendments are filed. This entry rate is in the 85% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 114.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 81% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 92.9% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 76.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 61.9% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 10.8% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.8% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.